India, May 12 -- Connect Biopharma Holdings Limited (CNTB), a clinical-stage biopharmaceutical company, on Tuesday announced its first quarter financial results, and provided updates in the clinical trials for lead drug Rademikibart.
Q1 2026:
The company recorded a net loss of $19.39 million, or $0.34 per share in Q1 2026, while in the same period of 2025 the net loss was $10.27 million, or $0.19 per share.
Connect earned $0.20 million in licensing and collaboration revenues from Simcere, and is eligible for milestone payments up to $110 million on the achievement of certain development, regulatory and commercial milestones.
Research and development expenses (R&D) were $15.03 million, considerably higher than the $6.63 million reported ...